MetabolomicsWorkbenchapplication/xmlhttp://www.metabolomicsworkbench.org/rest/study/study_id/ST000677/mwtabprimaryOK200Mass SpectrometryESIFatty Liver Diseasehttp://www.metabolomicsworkbench.org/data/DRCCMetadata.php?Mode=Study&StudyID=ST000677visit:intitial visitvisit:initial visitvisit:month 12visit:closeoutvisit:month 1visit:visit 1BloodC18 NEGATIVE ION MODE. C18 POSITIVE ION MODE.MetabolomicsWorkbenchMetabolomicsHomo SapiensUniversity of MichiganFFA(18:0)PC 37:4; [M-Ac-H]-@6.68PC 35:3; [M-Ac-H]-@6.26SM 33:1; [M+Na]+@5.60MG 18:0; [M+NH4]+@3.72TG 42:2; [M+NH4]+@9.26TG 42:0; [M+NH4]+@9.79FFA(24:0)PC 36:1; [M-Ac-H]-@7.50TG 62:13; [M+NH4]+@9.93PC 34:6; [M+H]+@5.31TG 57:9; [M+NH4]+@10.05PC 34:1; [M+H]+@6.79TG 56:1; [M+NH4]+@11.34FFA(20:4) Arachidonic acidTG 62:14; [M+NH4]+@9.87DG 36:1; [M+NH4]+@8.50TG 52:7; [M+NH4]+@9.70SM 33:2; [M]+@5.06FFA(18:1)PI 38:4; [M-H]-@5.88PI 38:3; [M-H]-@6.10TG 52:1; [M+NH4]+@10.85plasmenyl-PE 40:6; [M-H]-@7.27TG 55:4; [M+NH4]+@10.62lysoPC 16:0; [M+H]+@1.62FFA(24:1)TG 53:1; [M+NH4]+@10.98MG 16:1; [M+NH4]+@2.06TG 58:7; [M+NH4]+@10.47TG 56:4; [M+NH4]+@10.77PE 38:3; [M-H]-@7.31CE(18:2); [M+NH4]+@10.66DG 36:2; [M+NH4]+@8.21PE 34:3; [M-H]-@6.05plasmenyl-PE 40:4; [M+H]+@7.88TG 53:3; [M+NH4]+@10.59plasmenyl-PC 44:4; [M+Na]+@8.63SM 42:2; [M+Na]+@7.93PE 36:5; [M-H]-@6.02plasmenyl-PC 36:4; [M+Na]+@6.70SM 44:2; [M+Na]+@8.49TG 53:0; [M+NH4]+@11.20DG 40:8; [M+NH4]+@7.18TG 55:0; [M+NH4]+@11.18TG 49:0; [M+NH4]+@10.72plasmenyl-PE 36:1; [M-H]-@7.82TG 50:0; [M+NH4]+@10.82lysoPE 22:5; [M-H]-@1.58PE 37:4; [M-H]-@6.72TG 58:5; [M+NH4]+@10.83PE 36:1; [M-H]-@7.53TG 60:10; [M+NH4]+@10.21TG 53:7; [M+NH4]+@9.83PE 35:1; [M+H]+@7.21TG 56:10; [M+NH4]+@9.72lysoPE 18:0; [M-H]-@2.49PC 42:10; [M-Ac-H]-@5.85plasmenyl-PE 42:6; [M+H]+@7.82TG 50:2; [M+NH4]+@10.36plasmenyl-PE 36:5; [M-H]-@6.36PC 36:3; [M-Ac-H]-@6.54SM 41:2; [M+Na]+@7.74PC 32:4; [M+H]+@5.56PE 35:2; [M-H]-@6.76TG 50:5; [M+NH4]+@9.77TG 51:3; [M+NH4]+@10.35TG 52:6; [M+NH4]+@9.84PI 36:2; [M-H]-@5.92TG 54:4; [M+NH4]+@10.46DG 40:6; [M+NH4]+@7.75PC 38:4; [M-Ac-H]-@6.89TG 54:6; [M+NH4]+@10.10SM 40:2; [M+Na]+@7.46TG 51:5; [M+NH4]+@9.97SM 42:0; [M+Na]+@8.04PC 40:7; [M-Ac-H]-@6.36TG 42:1; [M+NH4]+@9.54TG 48:2; [M+NH4]+@10.12TG 55:8; [M+NH4]+@10.02TG 50:3; [M+NH4]+@10.16plasmenyl-PE 32:1; [M-H]-@6.67TG 60:13; [M+NH4]+@9.77PC 30:3; [M+H]+@5.39PC 42:5; [M+Na]+@7.66TG 60:9; [M+NH4]+@10.39TG 40:0; [M+NH4]+@9.47TG 54:7; [M+NH4]+@9.92PC 35:4; [M+Na]+@6.07SM 36:1; [M+Na]+@6.67SM 34:2; [M+Na]+@5.39TG 54:0; [M+NH4]+@11.32TG 60:8; [M+NH4]+@10.57TG 49:2; [M+NH4]+@10.30TG 54:8; [M+NH4]+@9.75FFA(22:2)lysoPE 16:0; [M-H]-@1.69TG 54:3; [M+NH4]+@10.68DG 38:2; [M+NH4]+@8.43DG 34:0; [M+NH4]+@8.43plasmenyl-PC 44:4; [M+Na]+@8.51PC 37:5; [M+Na]+@6.11TG 57:6; [M+NH4]+@10.57PC 38:6; [M+H]+@6.21SM 35:1; [M+Na]+@6.07DG 40:5; [M+NH4]+@8.10plasmenyl-PC 42:4; [M+Na]+@8.07PC 36:2; [M+H]+@6.97lysoPE 22:6; [M-H]-@1.34plasmenyl-PE 34:3; [M-H]-@6.42PI 34:2; [M-H]-@5.26lysoPC 18:2; [M+H]+@1.35TG 62:1; [M+NH4]+@12.21PC 40:9; [M+H]+@5.53DG 34:4; [M+NH4]+@6.82PE 40:6; [M-H]-@6.97SM 32:2; [M+Na]+@4.63TG 49:1; [M+NH4]+@10.51PI 38:5; [M-H]-@5.40TG 56:5; [M+NH4]+@10.60PE 40:5; [M-H]-@7.25TG 44:1; [M+NH4]+@9.83PC 35:5; [M+H]+@6.11FFA(22:3)PC 38:2; [M-Ac-H]-@7.64PE 32:1; [M-H]-@6.31MG 17:0; [M+Li]+@3.20plasmenyl-PC 31:0; [M+Na]+@5.41TG 52:5; [M+NH4]+@9.94TG 62:15; [M+NH4]+@9.70PC 32:0; [M-Ac-H]-@6.77lysoPE 18:2; [M-H]-@1.40PC 36:6; [M+H]+@5.98FFA(16:0)TG 55:1; [M+NH4]+@11.22plasmenyl-PE 40:5; [M-H]-@7.35DG 33:2; [M+NH4]+@7.35N-(15Z-tetracosenoyl)-sphing-4-enine; [M-H]-@8.52PC 28:0; [M-Ac-H]-@5.41PG 38:4; [M-H]-@6.07PC 33:2; [M-Ac-H]-@6.11FFA(22:0)DG 36:0; [M+NH4]+@8.89PE 34:1; [M-H]-@6.94DG 35:1; [M+NH4]+@8.24TG 48:3; [M+NH4]+@9.92TG 49:4; [M+NH4]+@9.88DG 36:3; [M+NH4]+@7.71SM 42:1; [M+Na]+@8.43CerP 34:1; [M-H]-@5.96plasmenyl-PE 38:3; [M-H]-@7.62DG 34:3; [M+NH4]+@7.20DG 38:5; [M+NH4]+@7.54DG 35:2; [M+NH4]+@7.87PI 40:5; [M-H]-@5.99TG 53:6; [M+NH4]+@10.01lysoPE 20:4; [M-H]-@1.37SM 32:1; [M+Na]+@5.21SM 39:1; [M+Na]+@7.67DG 32:1; [M+NH4]+@7.51TG 56:2; [M+NH4]+@11.12PC 33:1; [M-Ac-H]-@6.59lysoPC 22:0; [M+H]+@4.37DG 31:0; [M+NH4]+@7.60PC 37:7; [M+H]+@6.05PG 36:2; [M-H]-@6.08PC 40:4; [M-Ac-H]-@7.45CL 74:3; [M-2H](2-)@7.01PC 32:1; [M-Ac-H]-@6.25PE 40:4; [M-H]-@7.50TG 48:1; [M+NH4]+@10.34plasmenyl-PE 34:1; [M-H]-@7.27plasmenyl-PE 34:2; [M-H]-@6.78TG 56:3; [M+NH4]+@10.92PC 40:6; [M-Ac-H]-@6.81PC 36:4; [M+H]+@6.02SM 34:1; [M]+@5.90TG 56:0; [M+NH4]+@11.60TG 60:11; [M+NH4]+@10.11TG 56:9; [M+NH4]+@9.86TG 62:9; [M+NH4]+@10.56plasmenyl-PE 36:4; [M-H]-@6.73plasmenyl-PE 38:6; [M-H]-@6.62TG 51:4; [M+NH4]+@10.17PE 40:8; [M-H]-@6.04PC 36:5; [M-Ac-H]-@5.84lysoPC 20:3; [M+Na]+@1.36TG 58:11; [M+NH4]+@9.80TG 58:12; [M+NH4]+@9.62PE 36:0; [M-H]-@7.95DG 36:5; [M+NH4]+@6.99PG 33:0; [M-H]-@6.10PE 38:6; [M-H]-@6.20TG 53:2; [M+NH4]+@10.78lysoPE 20:5; [M-H]-@1.13DG 36:6; [M+NH4]+@6.66plasmenyl-PC 40:0; [M+Na]+@8.61TG 46:3; [M+NH4]+@9.65TG 58:6; [M+NH4]+@10.65PC 35:2; [M-Ac-H]-@6.70TG 55:5; [M+NH4]+@10.55TG 60:1; [M+NH4]+@11.88PE 34:2; [M-H]-@6.48TG 55:3; [M+NH4]+@10.82TG 58:8; [M+NH4]+@10.32PC 38:5; [M-Ac-H]-@6.52PE 32:0; [M-H]-@6.81PI 36:4; [M-H]-@5.26lysoPC 24:1; [M+H]+@4.41MG 15:1; [M+NH4]+@0.88TG 57:2; [M+NH4]+@11.25N-(hexadecanoyl)-sphing-4-enine; [M-H]-@6.89PI 38:6; [M-H]-@5.14CL 66:1; [M-2H](2-)@6.29PC 34:2; [M+H]+@6.32MG 16:0; [M+NH4]+@2.81PC 30:1; [M-Ac-H]-@5.55TG 58:10; [M+NH4]+@9.98TG 54:2; [M+NH4]+@10.80TG 55:7; [M+NH4]+@10.14PC 40:5; [M-Ac-H]-@7.22PE 36:4; [M-H]-@6.28FFA(20:2)PC 37:3; [M-Ac-H]-@6.86lysoPC 22:4; [M+H]+@1.91PE 36:2; [M-H]-@7.07lysoPE 22:4; [M-H]-@1.99TG 52:2; [M+NH4]+@10.60TG 56:8; [M+NH4]+@10.07PC 30:0; [M-Ac-H]-@6.11TG 52:4; [M+NH4]+@10.21PC 38:3; [M-Ac-H]-@7.26TG 58:3; [M+NH4]+@11.17plasmenyl-PE 36:3; [M-H]-@7.00TG 49:3; [M+NH4]+@10.09lysoPC 20:2; [M+H]+@1.79PC 40:10; [M+H]+@5.61PE 38:1; [M-H]-@7.53PC 39:8; [M+H]+@6.12PC 42:8; [M+H]+@7.21PC 31:0; [M+Na]+@5.71PC 37:2; [M-Ac-H]-@7.38TG 53:5; [M+NH4]+@10.20TG 55:2; [M+NH4]+@11.02PC 38:9; [M+Na]+@5.15PI 37:4; [M-H]-@5.59TG 46:0; [M+NH4]+@10.33TG 46:1; [M+NH4]+@10.08DG 38:3; [M+NH4]+@8.24PE 38:5; [M-H]-@6.57PI 40:6; [M-H]-@5.83PE 36:3; [M-H]-@6.62TG 54:1; [M+NH4]+@11.10PC 42:7; [M+H]+@7.60TG 58:1; [M+NH4]+@11.60PC 42:11; [M+H]+@5.88plasmenyl-PE 38:4; [M-H]-@7.31PI 34:1; [M-H]-@5.71TG 58:4; [M+NH4]+@10.97SM 40:1; [M+Na]+@7.87plasmenyl-PE 42:5; [M-H]-@7.95TG 60:12; [M+NH4]+@9.90PC 32:2; [M-Ac-H]-@5.74lysoPC 19:0; [M+H]+@2.99plasmenyl-PE 36:2; [M-H]-@7.36SM 43:1; [M+Na]+@8.54TG 40:1; [M+NH4]+@9.18plasmenyl-PE 38:5; [M-H]-@6.83SM 41:1; [M+Na]+@8.18FFA(20:0)SM 30:1; [M+Na]+@4.45TG 58:2; [M+NH4]+@11.37PE 38:4; [M-H]-@7.02TG 56:7; [M+NH4]+@10.23TG 51:1; [M+NH4]+@10.75lysoPC 18:0; [M+H]+@2.45SM 43:2; [M+Na]+@8.28SM 42:5; [M]+@6.61TG 50:4; [M+NH4]+@9.97DG 38:1; [M+NH4]+@8.62TG 44:2; [M+NH4]+@9.58SM 42:4; [M]+@7.01TG 56:6; [M+NH4]+@10.43PC 40:2; [M-Ac-H]-@8.28PC 40:8; [M+H]+@6.61PC 36:7; [M+H]+@5.56TG 60:7; [M+NH4]+@10.71FFA(20:1)DG 30:1; [M+NH4]+@6.93SM 38:2; [M+Na]+@6.81TG 58:9; [M+NH4]+@10.18CE(20:4); [M+NH4]+@10.56DG 38:4; [M+NH4]+@7.91plasmenyl-PC 38:0; [M+Na]+@8.07DG 32:0; [M+NH4]+@7.97plasmenyl-PE 38:2; [M-H]-@7.97DG 33:0; [M+NH4]+@8.15TG 60:6; [M+NH4]+@10.96SM 36:2; [M+Na]+@6.13DG 38:7; [M+NH4]+@6.92FFA(18:2)TG 51:2; [M+NH4]+@10.55FFA(24:2)PE 40:7; [M-H]-@6.47PC 34:4; [M-Ac-H]-@5.62lysoPE 20:3; [M-H]-@1.68DG 32:2; [M+NH4]+@7.09PC 34:3; [M-Ac-H]-@5.93TG 55:6; [M+NH4]+@10.31plasmenyl-PC 40:3; [M+Na]+@8.08PC 38:7; [M-Ac-H]-@5.65SM 35:2; [M+Na]+@5.81DG 38:6; [M+NH4]+@7.30PE 38:2; [M-H]-@6.95DG 33:1; [M+NH4]+@7.76N-(tetracosanoyl)-sphing-4-enine; [M-H]-@8.96PC 37:6; [M-Ac-H]-@5.92plasmenyl-PE 40:3; [M-H]-@8.13TG 54:5; [M+NH4]+@10.27TG 52:0; [M+NH4]+@11.08TG 46:2; [M+NH4]+@9.85PC 38:8; [M+H]+@5.39SM 38:1; [M+Na]+@7.34CL 70:5; [M-2H](2-)@6.00TG 54:9; [M+NH4]+@9.70MG 18:2; [M+NH4]+@2.36PC 32:3; [M+H]+@6.13TG 50:1; [M+NH4]+@10.54PA 34:2; [M-H]-@6.38lysoPE 18:1; [M-H]-@1.86TG 52:3; [M+NH4]+@10.42DG 30:0; [M+NH4]+@7.39DG 34:2; [M+NH4]+@7.65TG 53:4; [M+NH4]+@10.39FFA(24:3)Steatohepatitides, NAFLD, Fatty Livers, Liver, Ob Gene Product, MASH, Nonalcoholic Fatty Liver, nonalcoholic steatohepatitis, non alcoholic steatohepatitis, NASH - nonalcoholic steatohepatitis, Steatohepatitis, Ob., Gene Product, Nonalcoholic Steatohepatitis, Livers, Obese, Obese Gene Product, Nonalcoholic Fatty, NASH, metabolic dysfunction-associated steatohepatitis, Non alcoholic Fatty Liver Disease, Fatty Liver, Nonalcoholic Fatty Livers, Nonalcoholic Fatty Liver Disease, Ob Protein, Nonalcoholic Steatohepatitides, Obese Protein, Nonalcoholic, non-alcoholic steatohepatitisC18, D1, PTHB1, B1, B1.falseNonalcoholic steatohepatitis (NASH) changes with S.Q. Leptin administrationsST0006779606